guest ::
| Home > Publications Database > Treatment of a genetic brain disease by CNS-wide microglia replacement. > print |
| Home > Publications Database > Treatment of a genetic brain disease by CNS-wide microglia replacement. > print |
| 001 | 163738 | ||
| 005 | 20230915090534.0 | ||
| 024 | 7 | _ | |a pmc:PMC9618306 |2 pmc |
| 024 | 7 | _ | |a 10.1126/scitranslmed.abl9945 |2 doi |
| 024 | 7 | _ | |a pmid:35294256 |2 pmid |
| 024 | 7 | _ | |a 1946-6234 |2 ISSN |
| 024 | 7 | _ | |a 1946-6242 |2 ISSN |
| 024 | 7 | _ | |a altmetric:124752153 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-00477 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 500 |
| 100 | 1 | _ | |a Shibuya, Yohei |0 0000-0002-8825-5440 |b 0 |
| 245 | _ | _ | |a Treatment of a genetic brain disease by CNS-wide microglia replacement. |
| 260 | _ | _ | |a Washington, DC |c 2022 |b AAAS |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1650554305_20569 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Hematopoietic cell transplantation after myeloablative conditioning has been used to treat various genetic metabolic syndromes but is largely ineffective in diseases affecting the brain presumably due to poor and variable myeloid cell incorporation into the central nervous system. Here, we developed and characterized a near-complete and homogeneous replacement of microglia with bone marrow cells in mice without the need for genetic manipulation of donor or host. The high chimerism resulted from a competitive advantage of scarce donor cells during microglia repopulation rather than enhanced recruitment from the periphery. Hematopoietic stem cells, but not immediate myeloid or monocyte progenitor cells, contained full microglia replacement potency equivalent to whole bone marrow. To explore its therapeutic potential, we applied microglia replacement to a mouse model for Prosaposin deficiency, which is characterized by a progressive neurodegeneration phenotype. We found a reduction of cerebellar neurodegeneration and gliosis in treated brains, improvement of motor and balance impairment, and life span extension even with treatment started in young adulthood. This proof-of-concept study suggests that efficient microglia replacement may have therapeutic efficacy for a variety of neurological diseases. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Bone Marrow Cells |2 MeSH |
| 650 | _ | 2 | |a Brain |2 MeSH |
| 650 | _ | 2 | |a Brain Diseases |2 MeSH |
| 650 | _ | 2 | |a Central Nervous System |2 MeSH |
| 650 | _ | 2 | |a Hematopoietic Stem Cell Transplantation |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Microglia |2 MeSH |
| 700 | 1 | _ | |a Kumar, Kevin K |0 0000-0002-0704-1492 |b 1 |
| 700 | 1 | _ | |a Mader, Marius Marc-Daniel |0 0000-0002-7467-9672 |b 2 |
| 700 | 1 | _ | |a Yoo, Yongjin |b 3 |
| 700 | 1 | _ | |a Ayala, Luis Angel |0 0000-0002-6272-3314 |b 4 |
| 700 | 1 | _ | |a Zhou, Mu |0 0000-0001-5326-4884 |b 5 |
| 700 | 1 | _ | |a Mohr, Manuel Alexander |0 0000-0002-5189-541X |b 6 |
| 700 | 1 | _ | |a Neumayer, Gernot |b 7 |
| 700 | 1 | _ | |a Kumar, Ishan |0 0000-0001-6847-9706 |b 8 |
| 700 | 1 | _ | |a Yamamoto, Ryo |b 9 |
| 700 | 1 | _ | |a Marcoux, Paul |b 10 |
| 700 | 1 | _ | |a Liou, Benjamin |b 11 |
| 700 | 1 | _ | |a Bennett, F Chris |b 12 |
| 700 | 1 | _ | |a Nakauchi, Hiromitsu |0 0000-0002-9841-6973 |b 13 |
| 700 | 1 | _ | |a Sun, Ying |b 14 |
| 700 | 1 | _ | |a Chen, Xiaoke |0 0000-0001-9032-9093 |b 15 |
| 700 | 1 | _ | |a Heppner, Frank |0 P:(DE-2719)2812386 |b 16 |u dzne |
| 700 | 1 | _ | |a Wyss-Coray, Tony |0 0000-0001-5893-0831 |b 17 |
| 700 | 1 | _ | |a Südhof, Thomas C |0 0000-0003-3361-9275 |b 18 |
| 700 | 1 | _ | |a Wernig, Marius |0 0000-0002-5309-515X |b 19 |
| 773 | _ | _ | |a 10.1126/scitranslmed.abl9945 |g Vol. 14, no. 636, p. eabl9945 |0 PERI:(DE-600)2518839-2 |n 636 |p eabl9945 |t Science translational medicine |v 14 |y 2022 |x 1946-6234 |
| 909 | C | O | |o oai:pub.dzne.de:163738 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2812386 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-30 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b SCI TRANSL MED : 2021 |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-16 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b SCI TRANSL MED : 2021 |d 2022-11-16 |
| 920 | 1 | _ | |0 I:(DE-2719)1810007 |k AG Heppner |l Neuroimmunology |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1810007 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|